These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 1715635

  • 1. Long-term culture growth of CD4-CD8- lymphocytes exhibiting elevated non-MHC-restricted cytotoxic activity.
    Montesoro E, Bulgarini D, Carè A, Masciulli R, Giannella G, Mariani G, Samoggia P, Salvo G, Habetswallner D, Testa U.
    J Biol Regul Homeost Agents; 1991; 5(1):10-8. PubMed ID: 1715635
    [Abstract] [Full Text] [Related]

  • 2. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S.
    J Immunol; 1992 Jan 01; 148(1):285-91. PubMed ID: 1345787
    [Abstract] [Full Text] [Related]

  • 3. Molecular studies on LAK cells.
    Fagioli M, Carè A, Ciccone E, Moretta L, Moretta A, Testa U, Falini B, Grignani F, Peschle C, Pelicci PG.
    Ann Ist Super Sanita; 1990 Jan 01; 26(3-4):357-68. PubMed ID: 1982603
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH.
    Cancer Res; 1989 Feb 15; 49(4):963-8. PubMed ID: 2521457
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 Feb 15; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.
    Testa U, Care A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G.
    Cancer Immunol Immunother; 1990 Feb 15; 31(1):11-8. PubMed ID: 2306752
    [Abstract] [Full Text] [Related]

  • 7. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
    Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC.
    J Immunol; 1991 May 15; 146(10):3289-97. PubMed ID: 1827481
    [Abstract] [Full Text] [Related]

  • 8. Antigen specific and MHC nonrestricted cytotoxicity of T cell receptor alpha beta+ and gamma delta+ human T cell clones isolated in IL-4.
    Paliard X, Yssel H, Blanchard D, Waitz JA, deVries JE, Spits H.
    J Immunol; 1989 Jul 15; 143(2):452-7. PubMed ID: 2472439
    [Abstract] [Full Text] [Related]

  • 9. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
    Cesano A, Visonneau S, Clark SC, Santoli D.
    J Immunol; 1993 Sep 15; 151(6):2943-57. PubMed ID: 8104216
    [Abstract] [Full Text] [Related]

  • 10. Non-MHC-restricted target-cell lysis by a CD4-CD8- TCR alpha beta T-cell line, as well as by TCR gamma delta T-cell lines, results from lymphokine-activated killing.
    Maziarz RT, Groh V, Prendergast M, Fabbi M, Strominger JL, Burakoff SJ.
    Int J Cancer; 1991 Apr 22; 48(1):142-7. PubMed ID: 1902200
    [Abstract] [Full Text] [Related]

  • 11. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 12. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, Nomoto K.
    Cancer Res; 1991 Mar 01; 51(5):1494-8. PubMed ID: 1997188
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY.
    Cancer Res; 1995 Nov 01; 55(21):4988-94. PubMed ID: 7585540
    [Abstract] [Full Text] [Related]

  • 14. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS.
    Cancer Res; 1991 Aug 15; 51(16):4257-65. PubMed ID: 1868446
    [Abstract] [Full Text] [Related]

  • 15. Lymphokine-activated killer cell activity of CD4-CD8- TCR alpha beta + thymocytes.
    Arase H, Arase-Fukushi N, Good RA, Onoé K.
    J Immunol; 1993 Jul 15; 151(2):546-55. PubMed ID: 8335898
    [Abstract] [Full Text] [Related]

  • 16. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
    Lanier LL, Le AM, Cwirla S, Federspiel N, Phillips JH.
    Fed Proc; 1986 Nov 15; 45(12):2823-8. PubMed ID: 3095151
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G, Malorni W, Donelli G.
    Ann Ist Super Sanita; 1990 Nov 15; 26(3-4):369-84. PubMed ID: 2151107
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.